The first study was a phase 1 trial examining the safety and efficacy of the SMO inhibitor BMS-833923 (XL-139; Bristol Myers Squib) in patients with chronic phase CML (CML-CP) who failed or responded sub-optimally to prior TKI or with accelerated phase CML (CML-AP) or Ph + acute lymphoblastic leukemia (ALL) resistant to imatinib or nilotinib [28]. Here, SMO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.